PMID- 9833762
OWN - NLM
STAT- MEDLINE
DCOM- 19981204
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 78
IP  - 6
DP  - 1998 Dec 9
TI  - Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ 
      melanoma patients have a memory phenotype.
PG  - 699-706
AB  - Melan-A/MART-1 is a melanoma differentiation antigen that is recognized by a high 
      proportion of cytolytic T lymphocyte (CTL) clones derived from human leukocyte 
      antigen (HLA)-A2+ melanoma patients. Whereas peptide Melan-A/ MART-1(27-35) was 
      originally defined as the immunodominant CTL epitope, we have previously reported 
      that peptide Melan-A/MART-1(26-35) was recognized more efficiently by the 
      majority of tumor-reactive CTL clones. As demonstrated here, CTL populations 
      generated from blood lymphocytes of either melanoma patients or healthy 
      individuals after in vitro stimulation with peptide Melan-A/MART-1(26-35) killed 
      specifically HLA-A2+ Melan-A+ allogeneic melanoma cells, thus suggesting their 
      potential use in adoptive immunotherapy. We characterized the surface phenotype 
      of the circulating CTL precursors (CTLp), which respond to in vitro stimulation 
      with peptide Melan-A/MART-1(26-35). In melanoma patients, these CTLp 
      predominantly expressed the CD45RO memory marker. In contrast, they were mainly, 
      although not exclusively, found in the CD45RA subpopulation of CD8 T cells in 
      healthy individuals. The demonstration that Melan-A/MART-1-specific CTLp in 
      peripheral blood lymphocytes from HLA-A2+ patients with metastatic melanoma 
      express a memory phenotype provides direct evidence that in vivo priming of this 
      antigen may occur during tumor progression.
FAU - D'Souza, S
AU  - D'Souza S
AD  - Multidisciplinary Oncology Center, CHUV, Lausanne, Switzerland.
FAU - Rimoldi, D
AU  - Rimoldi D
FAU - Lienard, D
AU  - Lienard D
FAU - Lejeune, F
AU  - Lejeune F
FAU - Cerottini, J C
AU  - Cerottini JC
FAU - Romero, P
AU  - Romero P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (MART-1 Antigen)
RN  - 0 (MLANA protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
SB  - IM
MH  - Antigens, Neoplasm
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - HLA-A2 Antigen/*immunology
MH  - Humans
MH  - *Immunologic Memory
MH  - Leukocyte Common Antigens/metabolism
MH  - MART-1 Antigen
MH  - Melanoma/*immunology
MH  - Neoplasm Proteins/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 1998/12/02 03:03
MHDA- 2000/06/20 09:00
CRDT- 1998/12/02 03:03
PHST- 1998/12/02 03:03 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1998/12/02 03:03 [entrez]
AID - 10.1002/(SICI)1097-0215(19981209)78:6<699::AID-IJC6>3.0.CO;2-U [pii]
AID - 10.1002/(sici)1097-0215(19981209)78:6<699::aid-ijc6>3.0.co;2-u [doi]
PST - ppublish
SO  - Int J Cancer. 1998 Dec 9;78(6):699-706. doi: 
      10.1002/(sici)1097-0215(19981209)78:6<699::aid-ijc6>3.0.co;2-u.